- Home
- RAMP vs ARDX Comparison
RAMP vs ARDX Comparison
Compare RAMP & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- ARDX
- Stock Information
- Founded
- RAMP 2018
- ARDX 2007
- Country
- RAMP United States
- ARDX United States
- Employees
- RAMP N/A
- ARDX N/A
- Industry
- RAMP EDP Services
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- RAMP Technology
- ARDX Health Care
- Exchange
- RAMP Nasdaq
- ARDX Nasdaq
- Market Cap
- RAMP 1.6B
- ARDX 1.4B
- IPO Year
- RAMP 1987
- ARDX 2014
- Fundamental
- Price
- RAMP $27.90
- ARDX $4.97
- Analyst Decision
- RAMP Buy
- ARDX Buy
- Analyst Count
- RAMP 7
- ARDX 7
- Target Price
- RAMP $41.14
- ARDX $11.75
- AVG Volume (30 Days)
- RAMP 514.5K
- ARDX 5.4M
- Earning Date
- RAMP 11-06-2024
- ARDX 10-31-2024
- Dividend Yield
- RAMP N/A
- ARDX N/A
- EPS Growth
- RAMP N/A
- ARDX N/A
- EPS
- RAMP 0.04
- ARDX N/A
- Revenue
- RAMP $707,165,000.00
- ARDX $251,849,000.00
- Revenue This Year
- RAMP $12.97
- ARDX $167.24
- Revenue Next Year
- RAMP $8.72
- ARDX $18.93
- P/E Ratio
- RAMP $635.45
- ARDX N/A
- Revenue Growth
- RAMP 13.84
- ARDX 87.57
- 52 Week Low
- RAMP $21.45
- ARDX $4.01
- 52 Week High
- RAMP $42.66
- ARDX $10.13
- Technical
- Relative Strength Index (RSI)
- RAMP 62.83
- ARDX 40.39
- Support Level
- RAMP $24.72
- ARDX $4.43
- Resistance Level
- RAMP $29.20
- ARDX $6.53
- Average True Range (ATR)
- RAMP 0.79
- ARDX 0.42
- MACD
- RAMP 0.29
- ARDX -0.12
- Stochastic Oscillator
- RAMP 69.64
- ARDX 28.73
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.